Toric posterior chamber phakic lens is safe and effective at one year

Article

According to Alaa El Danasoury and colleagues, Toric ICL (TICL; STAAR Surgical) implantation is safe, effective and predictable in its correction of compound myopic astigmatism.

According to Alaa El Danasoury and colleagues, Toric ICL (TICL; STAAR Surgical) implantation is safe, effective and predictable in its correction of compound myopic astigmatism.

A prospective study conducted at the Magrabi Eye Hospital, Jeddah, Saudi Arabia, enrolled 32 eyes of 21 patients to receive a myopic Toric ICL through a temporal clear corneal incision. All eyes had spherical equivalent (SE) refraction between -5.00 and -15.00 D, spectacle corrected visual acuity (VA) of 20/20 or better, stable manifest refraction for at least one year, endothelial cell counts above 2,200 cell/mm2 and anterior chamber depths of 2.7 mm or more.

Preoperatively the mean SE refraction was -9.32±2.31 D. Twelve months postoperatively this had improved to -0.12±0.45 D. More than 88% of subjects had an uncorrected VA of 20/20 or better and 20/30 or better in all eyes. Two lines or more of spectacle corrected VA was gained by 22% of eyes, while axis misalignment occurred in one eye.

The researchers concluded that implantation of the Toric ICL appears to be effective, predictable and relatively safe for the correction of compound myopic astigmatism, though longer follow-up would be necessary to validate this claim.

A second study conducted by Baha Toygar and co-workers from the Dunya Eye Hospital, Istanbul, Turkey further supported the safety and efficacy of the TICL for the correction of high levels of myopic astigmatism.

A prospective study was conducted that included 27 eyes of 17 subjects whose mean preoperative SE was -10.74±2.17 D, and whose mean preoperative astigmatism was recorded at -2.65±1.03 D. In each patient, the TICL was inserted in the anterior chamber through a temporal corneal incision. After implantation into the sulcus the lens was rotated to the correct axis.

Postoperatively, mean SE was -0.67±1.00 D and mean residual astigmatic error was 0.50±0.45 D. A total of 67% of the eyes were within ±0.50 D of emmetropia and 82% ±1.0 D. Preoperative uncorrected VA improved from 0.02±0.01 to 0.65±0.24 and best corrected VA improved from 0.52±0.23 to 0.78±0.22. In one eye, TICL exchange was performed because of high amounts of vaulting. Furthermore, cataract surgery was performed in one eye after repositioning and then exchanging the TICL.

Toygar concluded that the TICL implantation procedure is both safe and effective.

Ophthalmology Times Europe reporting from the XXIV Congress of the ESCRS, London, 9-13 September, 2006.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.